The short answer
Wegovy and Zepbound are FDA-approved for chronic weight management; Ozempic and Mounjaro are used off-label for weight loss but are the diabetes brands.
Ozempic specifically
Off-label for weight loss; on-label for diabetes. Wegovy is the on-label semaglutide for obesity.
BMI & eligibility
The on-label obesity criterion is BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, T2D, OSA, cardiovascular disease).
Check your BMI
BMI calculator
BMI 27-29.9 — eligible if comorbidity (T2D, hypertension, sleep apnea, PCOS).
BMI is one signal among several. Waist circumference, body composition, metabolic markers, and clinical history also matter — talk to a prescriber.
Insurance & coverage
Obesity coverage is inconsistent — many commercial plans exclude weight-loss drugs entirely. When covered, prior authorization needs BMI, a comorbidity, and documented lifestyle intervention. Cash-pay and compounded routes are common.
Check if your plan covers itWe earn affiliate commissions from listed providers. See our editorial standards.
Other GLP-1s for obesity
Ozempic for other conditions
Sources
Educational information, not medical advice. FDA-approval status reflects labeling as of 2026; off-label prescribing is legal and common but coverage varies.